recombinant salmon calcitonin
Recombinant proteinexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
1
Earliest trial started Oct 1, 2006 (NCT00421590)
Timeline
Indications
Approved for
Mechanism of action
- Calcitonin receptorAGONIST
CALCR agonist
peptide drug, oral salmon calcitonin
- CalcitoninSupplementation
CALC supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545415 ↗
Also known as
- recombinant salmon calcitonin (rsct)
- smc021
- smc021
- smc-021
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05805683 | N/A | May 1, 2023 | Tanta University |
| NCT03935984 | N/A | May 20, 2019 | ProMedica Health System, University of Toledo |
| NCT03342001 | Phase 4 | Jun 18, 2018 | University of Maryland |
| NCT00486434 | Phase 3 | May 1, 2007 | Nordic Bioscience, Novartis |
| NCT00525798 | Phase 3 | Mar 1, 2007 | Nordic Bioscience, Novartis |
| NCT00421590 | Phase 2 | Oct 1, 2006 | Novartis |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 3 | 1 | 2 | 2006 |
| Nordic Bioscience | For profit | 2 | 2 | 1 | 2007 |
| ProMedica Health System | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Tanta University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Toledo | Academic/Hospital | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1